期刊文献+

间日疟传播阻断疫苗Pvs25和Pvs28重组蛋白免疫活性的实验观察 被引量:3

Observations of immunocompetence on Plasmodium vivax transmission-blocking vaccine Pvs25 and Pvs28 recombinant proteins
下载PDF
导出
摘要 目的观察间日疟传播阻断疫苗候选抗原Pvs25和Pvs28重组蛋白免疫小鼠后抗体产生情况,从而探讨此两种候选抗原的免疫活性。方法用酵母菌表达的Pvs25和Pvs28重组蛋白皮下免疫DBA/2小鼠;采用ELISA方法,分别对各组小鼠免疫前后不同时间点血清中特异性IgG及其亚类IgG1、IgG2a的水平进行动态检测。结果初次免疫后第28dIgG及其亚类IgG1、IgG2a均出现有意义的升高(P<0.01),至第112dIgG及其亚类IgG1一直持续于较高的水平(P<0.01);而IgG2a水平则于初次免疫后第42d开始下降,但至112d仍高于免疫前及对照组(P<0.05)。结论Pvs25和Pvs28重组蛋白免疫DBA/2小鼠后可产生较高水平的特异性IgG抗体,并以IgG1亚类为主。 To observe the levels of antibodies induced by Pvs25 and Pvs28 immunization of mice and investigate the immunocompetence of the two recombinant proteins. The DBA/2 mice were subcutaneouly injected with rPvs25 or rPvs28 expressed in yeast emulsified in Freund's adjuvant. The level of IgG and its subclasses IgG1, IgG2a in serum obtained from each group mice at different times before or after vaccination were assayed by ELISA kits. The level of IgG, IgG1 and IgG2a increased on the day 28 after first vaccination(P 〈0.01), after this point the level of IgG and IgG1 were persisting on a very high level until day 112 and there was no evidence to decrease; although the level of IgG2a decresed rapidly after this peak ,its level of the recombinant protein group was higher than that of the control group till the 112 days after first vaccination (P〈0. 05). The rPvs25 and rPvs28 can induce the high level IgG,and the predominant subclass is IgG1. From these results, we conclude that the two recombinant proteins possess the ideal immunocompetence.
出处 《中国人兽共患病学报》 CAS CSCD 北大核心 2007年第6期598-600,共3页 Chinese Journal of Zoonoses
基金 国家自然科学基金资助项目(30371347)
关键词 间日疟原虫 传播阻断疫苗 PVS25 Pvs28 免疫活性 Plasmodium vivax transmission-blocking vaccine Pvs25 Pvs28 immunocompetence
  • 相关文献

参考文献12

  • 1Mendis K,Sina B J,Marchesini P,et al.The neglected burden of Plasmodium vivax malaria[J].Am J Trop Med Hyg,2001,64(1-2):97-106.
  • 2Gozar MM,Price VL,Kaslow DC.Saccharomyces cerevisiae-Secreted Fusion Proteins Pfs25 and Pfs28 Elicit Potent Plasmodium falciparum Transmission-Blocking Antibodies in mice[J].Infect immun,1998,66(1):59-64.
  • 3Tsuboi T,Kaslow DC,Gozar MM,et al.Sequence polymorphism in two novel plasmodium vivax ookinete surface proteins,Pvs25and Pvs28,that are malatia transmission-blocking vaccine candidates[J].Mol Med,1998,4:772-782.
  • 4郑丽,徐卫民,刘英杰,杨毅梅,曹雅明.间日疟原虫传播阻断疫苗候选抗原Pvs25中国分离株高度保守[J].中国寄生虫学与寄生虫病杂志,2004,22(1):16-19. 被引量:7
  • 5刘军,冯辉,郑丽,杨毅梅,金行一,曹雅明.我国云南分离株间日疟原虫传播阻断疫苗候选抗原pvs25基因多态性分析[J].中国人兽共患病杂志,2005,21(6):458-460. 被引量:6
  • 6Hisaeda H,Sowers AW,Tsuboi T,et al.Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes[J].Infec Immun,2000,68(12):6618-6623.
  • 7Arrighi RB,hurd H.The role of Plasmodium berghei ookinete proteins in binding to basal lamina components and transformation into oocysts[J].Int J Parasitol,2002,32(1):91-98.
  • 8Sieber KP,Huber M,Kaslow D,et al.The peritrophic membrane as a barrier:its penetration by Plasmodium gallinaceum and the effect of a monoclonal antibody to ookinetes[J].Exp Parasitol,1991,72(2):145-56.
  • 9Martinez AP,Margos G,Barker G,et al.The roles of the glycosylphosphatidylinositol anchor on the production and immunogenicity of recombinant ookinete surface antigen Pbs21 of Plasmodium berghei when prepared in a baculovirus expression system[J].Immunol,2000,22(10):493-500.
  • 10Sattabongkot J,Tsuboi T,Hisaeda H,et al.Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates[J].Am J Trop Med Hyg,2003,69(5):536-541.

二级参考文献22

  • 1Shi YP, Alpers MP, Povoa MM, et al. Single amino acid variationin the ookinete vaccine antigen from field isolates of Plasrnodiurn falciparurn [J]. Mol Biochem Parasitol, 1992,50:179-180.
  • 2WHO. Malaria transmission-blocking vaccine: An ideal public good.WHO document(TDR/RBM/MAL/VAC/2000.1 ) available from WHO,Geneva, and on website http://www. who. Int/tdr, 2000.
  • 3Hisaeda H, Stowers AW, Tsuboi T, et al. Antibodies to malariavaccine candidates Pvs25 and Pvs28 completdy block the ability of Plasrnodiurn vivax to infect mosquitoes[J]. Infect Immun, 2000,68: 6618-6623.
  • 4Tomas AM, Margos G, Dimopoulos G, et al. P25 and P28 proteinsof the malaria ookinete surface have multiple and partially redundant functions[J]. The EMBO Journal, 2001,20:3975-3983.
  • 5Tsuboi T, Kaslow DC, Gozar MM, et al. Sequence polymorphism intwo novel Plasrnodiurn vivax ookinete surface proteins, Pvs25 and Pvs28,that are malaria transmission-blocking vaccine candidates [ J ]. Mol Medl,1998,4: 772-782.
  • 6Sakihama N, Mitamura T, Kaneko A, et al. Long PCR amplification of Plasmodiurn falciparurn DNA extracted from filter paper blots[J].Exp Parasitol, 2001,97: 50-54.
  • 7Rozas J, Malaney P. DnaSP version 3: an integrated program formolecular population genetics and molecular evolution analysis[J]. Bioinformatics, 1999,15:174-175.
  • 8Tsuboi T, Tachibana M, Kaneko O, et al. Transmission-blockingvaccine of vivax malaria[J]. Parasitol Int, 2003,52:1-11.
  • 9Kaslow DC, Quakyi IA, Syin C, et al. A vaccine candidate from thesexual stage of human malaria that contains EGF-like domains[J]. Nature,1988,333: 74-76.
  • 10Barr PJ, Green KM, Gibson HL, et al. Recombinant Pfs25 proteinof Plasinodiurn falciparurn elicits malaria transmission-blocking immunityin experiment animals[J]. J Exp Med, 1991,174:1203-1208.

共引文献8

同被引文献87

引证文献3

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部